Nano-X Imaging (NNOX) Aktienübersicht
Nano-X Imaging Ltd. entwickelt ein kommerzielles tomographisches Bildgebungsgerät mit einer digitalen Röntgenquelle. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 0/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
NNOX Community Fair Values
Create NarrativeSee what 61 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Nano-X Imaging Ltd. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$1.93 |
| 52-Wochen-Hoch | US$5.72 |
| 52-Wochen-Tief | US$1.59 |
| Beta | 1.17 |
| 1 Monat Veränderung | 7.82% |
| 3 Monate Veränderung | -28.52% |
| 1 Jahr Veränderung | -65.10% |
| 3 Jahre Veränderung | -89.60% |
| 5 Jahre Veränderung | -93.50% |
| Veränderung seit IPO | -91.11% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 03
NNOX: New U.S. Distribution Agreement Will Support Future Imaging Deployment Upside
Analysts have trimmed their Nano-X Imaging price target by $2, reflecting updated views on the stock’s risk profile and long term earnings power after reassessing discount rate assumptions, projected revenue growth and profit margins. What's in the News Auditor Kesselman & Kesselman issued an unqualified opinion in Nano-X Imaging’s latest 20-F filing for the year ended Dec 31, 2025, while expressing doubt about the company’s ability to continue as a going concern.Seeking Alpha • May 12
Nano-X Imaging: Too Cheap To Ignore, Too Early To Buy
Summary Nano-X Imaging (NNOX) offers an integrated, FDA-cleared imaging platform targeting underserved clinics with affordable hardware, AI diagnostics, and teleradiology services. NNOX faces critical execution risk, with only 36 systems deployed and a $35M 2026 revenue target hinging on a significant ramp in the next two quarters. The company holds $60M in cash, burning $40M annually, and may require additional financing if revenue growth lags, posing dilution risk. I recommend holders wait for Q1 2026 results on May 20; potential buyers should remain on the sidelines until execution is demonstrated. Read the full article on Seeking Alpha
Narrativ-Update • Apr 26
NNOX: Reset Expectations And New Distribution Deals Could Support Upside
Analysts have trimmed their fair value estimate for Nano-X Imaging to $6.65 from $7.75 as they factor in updated assumptions around discount rates, long term revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent research has reset expectations around Nano-X Imaging, with analysts revisiting key inputs such as discount rates, long term revenue assumptions, margin potential, and future P/E levels.Recent updates
Narrativ-Update • Jun 03
NNOX: New U.S. Distribution Agreement Will Support Future Imaging Deployment Upside
Analysts have trimmed their Nano-X Imaging price target by $2, reflecting updated views on the stock’s risk profile and long term earnings power after reassessing discount rate assumptions, projected revenue growth and profit margins. What's in the News Auditor Kesselman & Kesselman issued an unqualified opinion in Nano-X Imaging’s latest 20-F filing for the year ended Dec 31, 2025, while expressing doubt about the company’s ability to continue as a going concern.Seeking Alpha • May 12
Nano-X Imaging: Too Cheap To Ignore, Too Early To Buy
Summary Nano-X Imaging (NNOX) offers an integrated, FDA-cleared imaging platform targeting underserved clinics with affordable hardware, AI diagnostics, and teleradiology services. NNOX faces critical execution risk, with only 36 systems deployed and a $35M 2026 revenue target hinging on a significant ramp in the next two quarters. The company holds $60M in cash, burning $40M annually, and may require additional financing if revenue growth lags, posing dilution risk. I recommend holders wait for Q1 2026 results on May 20; potential buyers should remain on the sidelines until execution is demonstrated. Read the full article on Seeking AlphaNarrativ-Update • Apr 26
NNOX: Reset Expectations And New Distribution Deals Could Support Upside
Analysts have trimmed their fair value estimate for Nano-X Imaging to $6.65 from $7.75 as they factor in updated assumptions around discount rates, long term revenue growth, profit margins, and future P/E levels. Analyst Commentary Recent research has reset expectations around Nano-X Imaging, with analysts revisiting key inputs such as discount rates, long term revenue assumptions, margin potential, and future P/E levels.Narrativ-Update • Apr 12
NNOX: New Distribution Agreements Will Support Future Imaging Deployment Upside
Analysts have kept their $5.00 price target for Nano-X Imaging unchanged, citing only slight adjustments to long term revenue growth assumptions, profit margins and future P/E expectations that do not materially change their view of the stock's valuation. What's in the News Nanox Impact signed a new distribution agreement with Elite Surgical Technologies to deploy the FDA cleared Nanox.ARC tomosynthesis system across Ohio, Indiana, Michigan, Pittsburgh and West Virginia, with expectations for a minimum of five systems in year one and ten in year two, subject to market conditions and customer adoption (Key Developments).Narrativ-Update • Mar 28
NNOX: New Global Imaging Deals And AI Platform Access Will Drive Upside
Analysts have adjusted their price target on Nano-X Imaging to $5.00. This keeps it in line with their fair value estimate as they update assumptions around revenue growth, profit margins and future P/E expectations.Narrativ-Update • Mar 12
NNOX: New Distribution Deals And AI Partnerships Will Drive Future Upside
Analysts have modestly adjusted their Nano-X Imaging price targets, reflecting small recalibrations to long term revenue growth expectations, slightly higher projected profit margins, and a marginally lower future P/E assumption. What's in the News Nano-X Imaging announced that its US-based subsidiary, Nanox Impact Inc., signed a new distribution agreement with Imperial Imaging Technology LLC to support the commercial rollout of the Nanox.ARC multisource digital tomosynthesis system across several southeastern US states.Narrativ-Update • Feb 25
NNOX: New Distribution Agreements And Software Rollout Will Support Future Upside Potential
Analysts have maintained their Nano-X Imaging fair value estimate at $5.00, citing only minor adjustments in projected revenue growth, profit margin, and future P/E assumptions instead of a significant change in their overall view. What's in the News Nano-X Imaging signed a distribution agreement with Intec SRL, which will act as the exclusive distributor for the Nanox.ARC system and related services in Argentina, covering marketing, distribution, installation, support, demonstrations, clinical evaluations, and training activities, with commercialization subject to required local regulatory approvals (Key Developments).Narrativ-Update • Feb 10
NNOX: New Collaborations And Equity Raise Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Nano-X Imaging from US$7.00 to US$5.00, citing updated assumptions around discount rates, long term revenue growth, profit margins, and a lower future P/E multiple. What's in the News The FDA granted 510(k) clearance for TAP2D, a cloud enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X systems.Narrativ-Update • Jan 27
NNOX: New Partnerships And Equity Raise Will Support Future Upside Potential
Analysts have modestly lifted their price target on Nano-X Imaging, citing an unchanged fair value at US$7.00, along with very large forecast revenue growth and slightly adjusted assumptions for the discount rate, profit margin and future P/E. What's in the News Nano-X Imaging filed and then completed a follow on equity offering of 3,826,530 ordinary shares, raising about US$15.0 million in a registered direct offering at US$3.92 per share, with a US$0.20 discount per share (Key Developments).Narrativ-Update • Jan 12
NNOX: New Partnerships And EU Approval Will Support Future Upside Potential
Analysts have lifted their price target on Nano-X Imaging to US$7.00. The updated view reflects higher modeled revenue growth and a lower projected future P/E multiple, while fair value and discount rate assumptions remain essentially unchanged.Narrativ-Update • Dec 26
NNOX: Expanding AI Imaging Partnerships Will Drive Future Global Deployment Upside
Analysts have nudged their price target on Nano-X Imaging slightly higher to reflect modest improvements in projected revenue growth, profit margins, and a marginally lower future price to earnings multiple. However, they have left their fair value estimate effectively unchanged at approximately 7.00 dollars per share.Narrativ-Update • Dec 12
NNOX Will Benefit From Expanding AI Imaging Partnerships And Growing Global Deployments
Analysts have raised their price target on Nano-X Imaging by approximately 17 percent to reflect stronger projected revenue growth and modestly improved long term profitability, which is partially offset by a slightly higher discount rate and a lower assumed future price to earnings multiple. What's in the News Nano-X Imaging completed a registered direct follow on equity offering of approximately $15 million, issuing 3,826,530 ordinary shares at $3.92 per share to support growth initiatives (company filing).Analyseartikel • Oct 31
Nano-X Imaging (NASDAQ:NNOX) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Narrativ-Update • Aug 15
Digital Diagnostics And AI Will Open Global Markets
With both Net Profit Margin and Consensus Revenue Growth forecasts holding steady, analyst expectations for Nano-X Imaging remain unchanged, maintaining the price target at $7.75. What's in the News Nano-X Imaging announced a clinical and educational collaboration with Keiser University to deploy the Nanox.ARC imaging system at the Sarasota campus for training and demonstrations.Analyseartikel • May 27
Analysts Have Just Cut Their Nano-X Imaging Ltd. (NASDAQ:NNOX) Revenue Estimates By 39%
One thing we could say about the analysts on Nano-X Imaging Ltd. ( NASDAQ:NNOX ) - they aren't optimistic, having just...
Neues Narrativ • Apr 27
FDA And CE Mark Approvals Will Open European Imaging Markets
FDA clearance and European market entry through CE mark approval may significantly enhance Nano-X Imaging's revenue and market presence.Analyseartikel • Apr 01
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Feb 14
Nano-X Imaging: When Will The Hockey Stick Growth Happen?
Summary Nano-X Imaging is my speculative play for disruptive innovation in the biotech sector. With the S&P 500 at historical highs, lagging sectors like healthcare seem relatively attractive. The biotech sector's large market size and potential make it an intriguing investment opportunity. The AI push in health sector is a long-term tailwind. NNOX is positioned well in offering real value from the AI system. Expect Nano-X to reach inflection point for revenue growth due to FDA approvals and the huge need for cost-effective X-ray monitoring and analyzing solutions. Read the full article on Seeking AlphaSeeking Alpha • Jan 04
Nano-X Imaging's Recent Surge Is Undeserved
Summary Nano-X Imaging shares surged 50.8% in a month, but I maintain a "sell' rating due to overvaluation and poor fundamentals. Despite some positive developments, Nano-X generates minimal revenue, significant net losses, and cash outflows, necessitating future capital raises. Recent FDA clearances and accolades are promising, but there's no concrete evidence that their technologies will achieve commercial success. The company's declining net cash balance and unjustified valuation reinforce my bearish stance on Nano-X Imaging. Read the full article on Seeking AlphaAnalyseartikel • Dec 05
We Think Some Shareholders May Hesitate To Increase Nano-X Imaging Ltd.'s (NASDAQ:NNOX) CEO Compensation
Key Insights Nano-X Imaging to hold its Annual General Meeting on 10th of December Total pay for CEO Erez Meltzer...Analyseartikel • Nov 25
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Sep 29
Nano-X Imaging: Bold Vision, Bearish Momentum, And High Investor Risk
Summary Nano-X Imaging has seen a significant decline in stock value, shedding over 37% since February, with no strong catalysts to reverse the trend. Nvidia’s small stake in Nano-X briefly boosted the stock, but without further investment or partnership, investor excitement has waned. Persistent financial losses, slow revenue growth, and limited global reach make Nano-X a high-risk investment with potential for further value erosion. Read the full article on Seeking AlphaAnalyseartikel • Apr 05
Is Nano-X Imaging (NASDAQ:NNOX) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 01
Nano-X Imaging: System Deployments Finally Begin
Summary Nano-X Imaging is executing its long-awaited roll-out strategy with multiple Nanox.ARC system deployments in the U.S. The company has also made progress in Africa and Latin America with installations and distribution agreements. However, financial performance is still lagging with scant details on how Nano-X will scale up to commercial scale. The story is improving, but there are still too many concerns for me to invest in NNOX stock. Read the full article on Seeking AlphaSeeking Alpha • Sep 28
Nano-X Imaging gains on FDA submission for new digital X-ray technology
Israel-based medical imaging firm Nano-X Imaging Ltd (NASDAQ:NNOX) added ~20% in the morning hours Wednesday after the company announced it submitted filings as part of a regulatory process to gain FDA’s 510(k) clearance for Nanox.ARC 3-D X-Ray system. In June 2021, the company announced the submission of a similar 510(k) premarket notification to the FDA for Nanox.ARC, also known as multi-source 3D digital tomosynthesis system. However, in August, NNOX said that the agency requested additional information related to the submission after finding deficiencies. NNOX received the FDA clearance for its single-source Nanox Cart X-Ray System in April 2021. Read: Seeking Alpha contributor Daniel Jones downgraded NNOX to Sell from Hold, citing the recent outperformance of its shares and concerns over profitability.Seeking Alpha • Aug 15
Nano-X Imaging Q2 Earnings Preview
Nano-X Imaging (NASDAQ:NNOX) is scheduled to announce Q2 earnings results on Tuesday, August 16th, before market open. The consensus EPS Estimate is -$0.25 (-38.9% Y/Y) and the consensus Revenue Estimate is $2.35M Over the last 1 year, NNOX has beaten EPS estimates 75% of the time and has beaten revenue estimates 25% of the time.Seeking Alpha • Jun 30
Nano-X: Too Controversial To Buy
Nano-X Imaging came to market with great fanfare in 2020, promising to disrupt the medical imaging market. After many FDA delays and short-selling controversies, the stock is down 90% from peak valuation. Despite the lowered valuation, there are too many risks for me to comfortably buy the name. After carefully reviewing Nano-X Imaging Ltd. (NNOX)'s history and controversies, I still struggle to justify the current valuation, despite it being down 90% from the peak. Despite easing downside momentum on the stock, I would recommend investors stay on the sidelines until the company can de-risk its story. Introduction I am approaching Nano-X Imaging Ltd. as a potential bottom fishing candidate. It has certainly been a rollercoaster ride for investors. Nano-X IPO’ed in August of 2020, and quickly tripled in value from its IPO price within weeks. However, there was a short attack shortly after from Citron and Muddy Waters broadly claiming that the company is built on vaporware and is “Theranos 2.0”. Figure 1 - NNOX shows interesting chart pattern (author created with price chart from stockcharts.com) While the company did not rebuke the short reports directly, it did schedule a live demonstration of its technology shortly after at the 2020 Radiology Society of North America (RSNA) conference in December. The successful demonstration of the prototype helped restore investor confidence somewhat and the stock price traded as high as $95 in early 2021, giving the company a market cap of almost $5 billion. Unfortunately, that was the high for NNOX’s stock price, as repeated FDA delays and the stock market correction helped crater the stock to a low of $8 recently. Since reaching $8 in March, the stock price is attempting to form a sustainable bottom, breaking the 2 year downtrend and challenging the 150 day moving average, with positive divergence in the MACD indicator. With this interesting technical backdrop, I want to revisit the company to see if it has made any progress fundamentally to justify a change in investor sentiment and/or successfully rebutted analyst critiques. Delays, Delays, And More Delays One of the biggest issues I have with the Nano-X story is its long history of delays. When Nano-X IPO'd, it initially planned to submit and obtain FDA clearance for its multiple-source Nanox.ARC X-Ray device by the fourth quarter of 2020: “We will continue to optimize and develop further features of the Nanox.ARC, and plan to submit an additional 510((K)) application under the Third Party Review Program with respect to the multiple-source Nanox.ARC during the fourth quarter of 2020, which, if cleared, will be our commercial imaging system.” -Quote from F-1 filed during IPO As the fourth quarter of 2020 came and went without FDA clearance even for its single-source Nanox.ARC, the company pushed back the commercial launch to Q1 2022: “We first demonstrated a working prototype of the Nanox.ARC in February 2020 and, if cleared by the FDA and authorized by similar regulatory agencies in other jurisdictions, we are targeting shipment of 1,000 Nanox Systems by the end of the first quarter of 2022, with the goal to finalize deployment of the initial 15,000 Nanox Systems by the end of 2024.” Quote from F1 filed during secondary offering of shares in February, 2021 Finally, in April of 2021, Nano-X did finally receive FDA clearance for its single-source Nanox Cart X-Ray System, almost a year after it initially submitted its 510 ((K)) application. However, with the Q1/2021 results that were released on May 11, 2021, the company further pushed out the commercialization date to sometime in 2022, blaming a shortage of high-power ceramic tubes: "As a result, while the Company does not expect to meet its previously announced milestone of shipment of 1,000 multi-source Nanox units by the first quarter of 2022, the Company believes that it will be able to gain ground during the year to reach the shipment milestone of 1,000 multi-source Nanox units during 2022, and possibly more, if the multi-source Nanox.ARC is cleared by the FDA and authorized by other similar regulatory agencies." Quote from Q1/2021 earnings release Moreover, the 510 ((K)) application for the multi-source Nanox.ARC appears to be mired with delays again. The company initially filed the 510 ((K)) in June 2021, but withdrew the submission in January of this year and replaced it with a Q-Submission instead (Q-submissions are requests for feedback and meetings). As can be imagined, the timeline to commercialization is pushed back even further, as the Nano-X still needs to clear the Q-Submission before resubmitting the 510 ((K)). "Right now, we don't say more than what we are seeing right now in the press release and in the earnings. The only thing I'm saying is that the fact that we have changed our way to communicate with the FDA to an on-day dialogue with a Q sub, we are waiting for the green light to the FDA for the approval of the Q sub and then it will be submitted, okay? We have provided in the last few months all the information that we requested. Following the last 2 sessions that we had with the FDA, they have asked for a lot of supplemental information. We have actually shared this information with the FDA. And right now, we are waiting for the okay." Erez Meltzer, CEO, on Q1/2022 earnings call So essentially, a FDA clearance on the multi-source Nanox.ARC is 2 years late, based on the original IPO timeline, with no clarity on if/when it will be received. Is The Technology Truly Disruptive? One good article that looked at the competitive landscape was written by Looking for Diogenes, who pointed out that an Australian competitor, Micro-X, filed a 510 ((K)) submission for their Rover Mobile X-Ray machine on June 11, 2020 and received clearance on July 20, 2020, so a much faster turnaround than what Nano-X has experienced. What I find interesting is that Nano-X appears to be the only company focused on a MEMs (Micro-Electromechanical Systems) solution while most of the recent literature appears focused on CNT (Carbon Nano-tube) technology. In fact, Micro-X, the company mentioned above, uses CNT to power their mobile X-Ray machines. It is quite odd for a groundbreaking technology to not have scholarly articles written about it. On an incidental note, in Diogenes’ article, he mentioned a third competitor, Carestream with a mobile X-Ray system on the market. In fact, upon closer due diligence, Micro-X appears to be the manufacturer of the Carestream Nano. Figure 2 - Micro-X is OEM manufacturer for Carestream mentioned in prior articles (Micro-X investor presentation) Without more information or disclosure, investors simply cannot make an educated assessment of Nano-X's technology. Short-Seller Controversy As we mentioned in the introduction, Nano-X was targeted by short sellers Citron and Muddy Waters shortly after it went public. Although I have no love for these dedicated short sellers, I do know one thing from my years running a hedge fund: when there's smoke, there's usually fire. It's rare for these short-sellers to target well run companies, as they can easily be sued for slander and stock manipulation. One common theme between the two short reports is that they took issue with Nano-X’s pre-order book. Nano-X claimed to have over 5,000 machines pre-ordered all across the world pending regulatory approval. FIgure 3 - NNOX's pre-order book (Nano-X F1 Filing) However, even a cursory due diligence on some of these customers would raise serious red flags. For example, shortly after the IPO, Nano-X press released that it had entered into a 7-year agreement with SPI Medical S.A. de C.V (Mexico) for 630 Nanox Systems across Mexico and Guatemala. However, a Google search of SPI Medical returns a very rudimentary "Hello World" webpage. Another customer, The Gateway Group of Australia, distributes consumer products and soft drinks. Hardly the required experience to distribute medical imaging equipment. The list goes on. On this controversial topic, I have to agree with the short sellers' analysis. How do legitimate medical imaging companies place orders for X-Ray and CT machines without FDA approval, clinical trials, and side-by-side comparisons of images, etc.? And if these were not legitimate customers, why heavily promote them in Nano-X presentations and marketing materials? And bringing the story back to Micro-X, the Australian firm with an existing mobile X-Ray machine that began selling in 2018, Micro-X has only seen $3.6 million (Figure 4) in revenues for FY2021. After 3 years on the market, a competing X-Ray machine has only achieved $3.6 million in revenue! The explanation I can think of is that the sales cycle for X-Ray machines is much longer than that assumed in the Nano-X presentation materials.Seeking Alpha • Mar 30
Nano-X Imaging Q4 2021 Earnings Preview: Insight Coming Regarding This Binary Play
Nano-X Imaging has been seeing losses and cash outflows mount as management gets closer to market. Nano-X has a lot going for it but it also has a steep hill to climb and only so much capital to do it with. NNOX is a binary play, but one that will soon reveal how things are currently progressing.Seeking Alpha • Dec 28
Monday's Drop Isn't Likely The Last One For Nano-X
Nano-X is a development stage company with no revenues and a high valuation - not uncommon in frothy markets. The share price has steadily been dropping and fell 7% Monday. Potentially, the company is a long way from profitability and it is my opinion the share price could drop further.Aktionärsrenditen
| NNOX | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 0.5% | 4.1% | -2.9% |
| 1Y | -65.1% | 16.8% | 23.5% |
Rendite im Vergleich zur Industrie: NNOX unter dem Niveau der Branche US Healthcare , die im vergangenen Jahr eine Rendite von 16.8% erzielte.
Rendite vs. Markt: NNOX hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 23.5 erzielte.
Preisvolatilität
| NNOX volatility | |
|---|---|
| NNOX Average Weekly Movement | 11.7% |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: Der Aktienkurs von NNOX war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: NNOXDie wöchentliche Volatilität (12%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2011 | 197 | Erez Meltzer | www.nanox.vision |
Nano-X Imaging Ltd. entwickelt ein kommerzielles tomographisches Bildgebungsgerät mit einer digitalen Röntgenquelle. Das Unternehmen bietet Teleradiologie-Dienstleistungen an und entwickelt Anwendungen der künstlichen Intelligenz, die in realen medizinischen Bildgebungsanwendungen eingesetzt werden können. Zu den Lösungen des Unternehmens gehören das Nanox Multi Source System mit Nanox
Nano-X Imaging Ltd.'s Grundlagenzusammenfassung
| NNOX grundlegende Statistiken | |
|---|---|
| Marktanteil | US$144.05m |
| Gewinn(TTM) | -US$75.02m |
| Umsatz(TTM) | US$13.02m |
10.3x
Kurs-Umsatz-Verhältnis-1.8x
Kurs-Gewinn-Verhältnis Ist NNOX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| NNOX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$13.02m |
| Kosten der Einnahmen | US$25.81m |
| Bruttogewinn | -US$12.79m |
| Sonstige Ausgaben | US$62.23m |
| Gewinn | -US$75.02m |
Zuletzt gemeldete Gewinne
Dec 31, 2025
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.08 |
| Bruttomarge | -98.21% |
| Nettogewinnspanne | -576.13% |
| Schulden/Eigenkapital-Verhältnis | 2.2% |
Wie hat sich NNOX auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/05 10:46 |
| Aktienkurs zum Tagesende | 2026/06/05 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Nano-X Imaging Ltd. wird von 9 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Benjamin Haynor | Alliance Global Partners |
| Scott Henry | Alliance Global Partners |
| Ravi Misra | Berenberg |